Lupin rolls out advanced triple-drug therapy inhaler for Indian COPD patients
- Lupin launches Formoflo-G MDI, a fixed-dose triple-combination inhaler for COPD treatment in India.
- The inhaler combines glycopyrronium bromide, formoterol fumarate and fluticasone propionate in one device.
- It is for long-term treatment of moderate to severe COPD and is taken twice daily as a single-strength dose.
- Lupin says the therapy could serve over 55 million people with COPD in India; it ranks second in respiratory therapy.
Source: economictimes.indiatimes.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
